Search
Corifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalIn July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug.
Products: Elonva Solution for Injection 150mcg/0.5ml, Elonva Solution for Injection 100mcg/0.5mlRemimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus … [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722]
Products: Byfavo 50mg Powder for Solution for Injection or Infusion (Lyophilised Powder) (Remimazolam Besylate)Paclitaxel
go.drugbank.com/drugs/DB01229ApprovedInvestigationalVet approvedIt is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. … Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel
Mixtures: Abraxane for Injectable Suspension 100mg, Abraxane for Injectable Suspension 100mgSynonyms: Paclitaxel protein-bound particles for injection suspensionMitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper
Products: MITONCO 10mg powder for solution for injection/infusion or intravesical, Mitomycin for InjectionClarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with am...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: CLARIFIC (Clarithromycin Lyophilized Powder for Solution for Infusion 500mg), KLACID IV FOR INJECTION 500 mg/vialLuspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigational[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic
Products: Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injectionUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[L64773] The FDA approved it for adults with moderately to severely active ulcerative colitis in October 2019.
Categories: Biologics for psoriasis treatmentProducts: STELARA CONCENTRATE FOR SOLUTION FOR INFUSION 130MG/26ML, STELARA 130mg/26mL Concentrate for Solution for InfusionTriptorelin
go.drugbank.com/drugs/DB06825ApprovedInvestigationalVet approvedTriptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous ad...
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsProducts: POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial, Pamorelin Powder for Suspension for Injection 3.75 mgAzacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigational[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]
Products: Azacitidine For, Vidaza powder for suspension for injection 100mg/vialRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]
Products: Skyrizi Concentrate for Solution for Infusion 600mg/10mL, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML